Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -13.63% is 269% below its 5-year average of -3.69%, near the low end of its 5-year range (-17.05%–11.11%).
29.07% below its 12-month average of -10.56%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 1.73%.
RETURN ON ASSETS (ROA)
-13.63%
RETURN ON ASSETS (ROA) AVG TTM
-10.56%
RETURN ON ASSETS (ROA) AVG 3Y
-3.47%
RETURN ON ASSETS (ROA) AVG 5Y
-3.69%
RETURN ON ASSETS (ROA) AVG 10Y
1.21%
RETURN ON ASSETS (ROA) AVG 15Y
-0.80%
RETURN ON ASSETS (ROA) AVG 20Y
0.34%
CURRENT VS TTM AVG
-29.07%
CURRENT VS 3Y AVG
-293.08%
CURRENT VS 5Y AVG
-269.38%
CURRENT VS 10Y AVG
-1224.76%
CURRENT VS 15Y AVG
-1602.42%
CURRENT VS 20Y AVG
-4067.98%
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+57.72%
vs the sector median at left
OraSure Technologies, Inc.
Market Cap
$261.97M
Return on Assets (ROA)
-13.63%
TTM Avg
-10.56%
3Y Avg
-3.47%
5Y Avg
-3.69%
Market Cap
$261.46M
Return on Assets (ROA)
-35.96%
TTM Avg
-58.88%
3Y Avg
-82.10%
5Y Avg
-113.46%
Market Cap
$260.79M
Return on Assets (ROA)
-35.62%
TTM Avg
-26.42%
3Y Avg
-45.47%
5Y Avg
-51.35%
Market Cap
$260.21M
Return on Assets (ROA)
-34.24%
TTM Avg
-52.06%
3Y Avg
-53.17%
5Y Avg
-44.53%
Market Cap
$261.24M
Return on Assets (ROA)
-25.09%
TTM Avg
-72.59%
3Y Avg
-80.80%
5Y Avg
-146.30%
Market Cap
$264.94M
Return on Assets (ROA)
-134.38%
TTM Avg
-47.50%
3Y Avg
-42.91%
5Y Avg
-40.55%
Market Cap
$264.63M
Return on Assets (ROA)
-37.07%
TTM Avg
-27.27%
3Y Avg
-64.53%
5Y Avg
-52.03%
Market Cap
$256.96M
Return on Assets (ROA)
-29.15%
TTM Avg
-33.84%
3Y Avg
-33.85%
5Y Avg
-31.54%
Market Cap
$272.46M
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| OraSure Technologies, Inc. (OSUR) | $261.97M | -13.63% | -10.56% | -3.47% | -3.69% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $261.46M | -35.96% | -58.88% | -82.10% | -113.46% |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $260.79M | -35.62% | -26.42% | -45.47% | -51.35% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $260.21M | -34.24% | -52.06% | -53.17% | -44.53% |
| Palisade Bio, Inc. (PALI)vs › | $261.24M | -25.09% | -72.59% | -80.80% | -146.30% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $264.94M | -134.38% | -47.50% | -42.91% | -40.55% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $264.63M | -37.07% | -27.27% | -64.53% | -52.03% |
| AC Immune S.A. (ACIU)vs › | $256.96M | -29.15% | -33.84% | -33.85% | -31.54% |
| Scribe Therapeutics Inc. (SCTX)vs › | $272.46M | N/A | N/A | N/A | N/A |
| Anika Therapeutics, Inc. (ANIK)vs › | $256.17M | -2.06% | -16.77% | -17.09% | -12.28% |
ROA
-13.6%
ROE
-15.5%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -17.05% |
| 2024-12-31 | -4.07% |
| 2023-12-31 | 11.11% |
| 2022-12-31 | -3.86% |
| 2021-12-31 | -4.99% |
| 2020-12-31 | -3.28% |
| 2019-12-31 | 4.77% |
| 2018-12-31 | 6.46% |
| 2017-12-31 | 10.45% |
| 2016-12-31 | 9.48% |
| 2015-12-31 | 4.31% |
| 2014-12-31 | -2.43% |
| 2013-12-31 | -6.07% |
| 2012-12-31 | -7.88% |
| 2011-12-31 | -6.91% |
| 2010-12-31 | -2.85% |
| 2009-12-31 | -6.15% |
| 2008-12-31 | -23.71% |
| 2007-12-31 | 1.48% |
| 2006-12-31 | 3.36% |
| 2005-12-31 | 20.99% |
| 2004-12-31 | -0.64% |
| 2003-12-31 | -1.32% |
| 2002-12-31 | -9.35% |
| 2001-12-31 | -10.00% |
| 2000-12-31 | -33.78% |
| 1999-09-30 | -29.91% |
| 1998-09-30 | -18.27% |
| 1997-09-30 | -132.35% |
| 1996-09-30 | -0.73% |
